Introduction:
Leading pharmaceutical company has secured exclusive rights to manufacture, market, and distribute Magnesium L-Threonate (MagteinĀ®) in India, leveraging its established expertise and aiming to capitalize on the product’s significant global market value.
Also Read: Ashish Kacholia stock jumps after it receives multiple orders
Share price movement of Bajaj Healthcare:
On January 17, 2025, Bajaj Healthcare Ltd opened at ā¹572.85, up 1.94% from its previous close of ā¹561.90. The stock reached a high of ā¹655.00 (16.57%) and a low of ā¹572.85. By 1:16 PM, it traded at ā¹644.60, a 14.72% increase, with a market cap of ā¹2,035.86 crore.
Bajaj Healthcare Secures Exclusive Rights for MagteinĀ® in India:
Bajaj Healthcare Limited announced securing exclusive rights to manufacture, market, and sell Magnesium L-Threonate (MagteinĀ®) in India from rights holder Threotech LLC. This milestone enhances Bajaj Healthcareās footprint in the Indian pharmaceutical market.
Under the agreement, Bajaj Healthcare gains licensing rights to produce MagteinĀ®’s finished formulation and collaborate with branded pharmaceutical firms for distribution. This move builds on the companyās expertise, as it already supplies the active pharmaceutical ingredient (API) for MagteinĀ® in the United States.
The MagteinĀ® brand, owned by Threotech LLC, has a sales value of approximately USD 438 million. Bajaj Healthcareās strategic expansion into India with exclusive manufacturing and marketing rights positions it to capture significant market potential in the country.
Recent news on Bajaj Healthcare:
As of December 30, 2024, Bajaj Healthcare Limited announced securing new CDMO contracts with UK and EU-based companies for 15 APIs, building on a similar agreement for 15 molecules signed in February 2024.
Stock performance of Bajaj Healthcare for Period of 1 week, 6 months and 1 year:
Bajaj Healthcare Ltd recorded a 4.64% rise over the past week, reflecting steady growth. Over six months, the stock surged 62.4%, while its impressive one-year return reached 61.5%, showcasing strong performance and investor confidence in the companyās prospects.
Also Read: Oil stock jumps after company signs ā¹31,802 Cr loan agreement for expansion of refinery in Bina
Shareholding pattern of Bajaj Healthcare:
| All values in % | Sep 2024 | Jun 2024 | Mar 2024 |
| Promoter | 59.20% | 59.20% | 67.70% |
| FII | 1.10% | 3% | 0% |
| DII | 2.00% | 2% | 0% |
| Public | 37.80% | 36.40% | 32.30% |
About Bajaj Healthcare:
Bajaj Healthcare Ltd (NSE: BAJAJHCARE) specializes in manufacturing active pharmaceutical ingredients (APIs), intermediates, and finished formulations. Renowned for innovation, the company caters to diverse industries, including pharmaceuticals and nutraceuticals, with a strong focus on quality and global market presence.
Disclaimer: The above article is written for educational purposes, and the companiesā data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
